T 2602/12 du 13.10.2016
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2016:T260212.20161013
- Date de la décision
- 13 octobre 2016
- Numéro de l'affaire
- T 2602/12
- Requête en révision de
- -
- Numéro de la demande
- 04741077.4
- Classe de la CIB
- A61L 27/26G02B 1/04G02C 7/04A61L 27/54
- Langue de la procédure
- Anglais
- Distribution
- Non distribuées (D)
- Téléchargement
- Décision en anglais
- Versions JO
- Aucun lien JO trouvé
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- -
- Titre de la demande
- ANTIMICROBIAL MEDICAL DEVICES
- Nom du demandeur
- Novartis AG
- Nom de l'opposant
- Johnson & Johnson Vision Care, Inc.
- Chambre
- 3.3.10
- Sommaire
- -
- Dispositions juridiques pertinentes
- European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal Art 12(2)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(3)
- Mots-clés
- Admissibility of main request (yes) - restriction of granted claim 1 to subject-matter for which no negative decision has been issued by the Opposition Division is legitimate behaviour of losing party, no abuse of procedure
Sufficiency of disclosure (yes)
Sufficiency of disclosure - sufficient guidance in patent in suit to make dispersions with the required stability
Inventive step (yes)
Inventive step - argument raised for first time at oral proceedings against embodiment of invention never previously attacked under Article 56 EPC not admitted; Board sees no reason to examine of its own motion - Exergue
- -
- Affaires citantes
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the Opposition Division with the order to maintain the patent on the basis of the main request (claim 1 as filed with letter dated 13 September 2016 and claims 2 to 14 as filed during the oral proceedings before the Board) and a description to be adapted.